Abstract Breast cancer is one of the most common causes of cancer-related deaths in women. The estrogen receptor (ERa) is well known for having growth promoting effects in breast cancer. Recently, we have identified DC-SCRIPT (ZNF366) as a co-suppressor of ERa and as a strong and independent prognostic marker in ESR1 (ERa gene)-positive breast cancer patients. In this study, we further investigated the molecular mechanism on how DC-SCRIPT inhibits breast cancer cell growth. DC-SCRIPT mRNA levels from 190 primary ESR1-positive breast tumors were related to global gene expression, followed by gene ontology and pathway analysis. The effect of DC-SCRIPT on breast cancer cell growth and cell cycle arrest was investigated using novel DC-SCRIPT-inducible MCF7 breast cancer cell lines. Genome-wide expression profiling of DC-SCRIPT-expressing MCF7 cells was performed to investigate the effect of DC-SCRIPT on cell cycle-related gene expression. Findings were validated by real-time PCR in a cohort of 1,132 ESR1-positive breast cancer patients. In the primary ESR1-positive breast tumors, DC-SCRIPT expression negatively correlated with several cell cycle gene ontologies and pathways. DC-SCRIPT expression strongly reduced breast cancer cell growth in vitro, breast tumor growth in vivo, and induced cell cycle arrest. In addition, in the presence of DC-SCRIPT, multiple cell cycles related genes were differentially expressed including the tumor suppressor gene CDKN2B. Moreover, in 1,132 primary ESR1-positive breast tumors, DC-SCRIPT expression also correlated with CDKN2B expression. Collectively, these data show that DC-SCRIPT acts as a novel regulator of CDKN2B and induces cell cycle arrest in ESR1-positive breast cancer cells.
Introduction
Breast cancer is the second most common malignancy in women, affecting one in eight in the US [1] . Improved knowledge on the molecular basis for breast cancer development has led to the identification of prognostic markers, enabling personalized treatment regimens beneficial for the patient [2] . Recently, we found that the nuclear receptor coregulator dendritic cell specific transcript [DC-SCRIPT, also known as zinc finger protein 366 (ZNF366)] has statistically significant prognostic value for patients with estrogen receptor alpha (ERa)-positive and/or progesterone receptor (PR)-positive tumors [3, 4] . It was shown that high DC-SCRIPT mRNA expression represents a solid prognostic marker as it predicts-independently of current clinical prognostic markers such as age, menopausal status, grade, tumor size and receptor status, increased disease-free, metastasis-free, and overall survival in patients who did not receive any adjuvant systemic treatment [3, 4] . Yet, little is known about the molecular mechanism on how DC-SCRIPT can inhibit breast cancer progression.
DC-SCRIPT was identified in 2006 and has been shown to play a versatile role in dendritic cells (DC) as well as cancer biology [3] [4] [5] [6] [7] [8] [9] [10] [11] . Within the immune system, DC-SCRIPT expression is limited to DCs [1] where it co-regulates Tolllike receptor-induced cytokine production [6] . In addition, we and others have shown that DC-SCRIPT acts as a coregulator of multiple nuclear receptors (NRs) [3, 7, 8, 11] . NRs are ligand-inducible transcription factors that can directly bind to DNA and thereby mediate transcription of genes involved in diverse biological processes, such as proliferation, differentiation, and metabolism [12] [13] [14] [15] . DC-SCRIPT was shown to interact with: the type I NRs ERa, PR, glucocorticoid receptor, and the androgen receptor; the type II NRs peroxisome proliferator-activator receptor (PPAR), retinoic acid receptor (RAR); and the vitamin D3 receptor [3, 7, 8] . While most NR co-regulators have a distinct activating or repressing function, co-repressors and co-activators can occasionally switch roles, depending on the promoter context [16] [17] [18] . Interestingly, we have shown that DC-SCRIPT also acts as a NR co-regulator having both repressing and activating capabilities [3] . Transcription mediated by the type I NRs was inhibited by DC-SCRIPT, while the activity of the type II NRs was enhanced by DC-SCRIPT. Remarkably, although several co-regulators exist that have a dual effect on NR function, to our knowledge, there are currently no co-regulators known to have such a distinct effect on type I and type II NR mediated transcription.
In line with the finding that DC-SCRIPT exhibits a repressive activity on the pro-proliferative type I NRs and enhances the mainly anti-proliferative activity of type II NRs, DC-SCRIPT expression in breast cancer cells results in the inhibition of breast cancer cell proliferation [3] . Proliferation of cells is a tightly regulated process to avoid malignant transformation. Cellular transformation has often been linked to lack of cell cycle control, and in general, three regulatory mechanisms are responsible for cell cycle progression; (1) the production and degradation of cyclins in oscillating cycles, (2) the (de)-phosphorylation of cyclin-dependent protein kinases (CDKs) and cyclins, and (3) the interaction of different CDK inhibitory proteins from the INK4 and Cip/Kip protein families with CDK/cyclin-complexes. While the Cip/Kip family members have a wide range of CDK/cyclin-complex specificities, the INK4 family members more specifically inhibit CDK/cyclin D complexes, thereby arresting cells in the G1 phase of cell cycle progression. Interestingly, many of the INK4/Cip/Kip family members have been shown to play an important role in breast cancer [19] [20] [21] .
Here, we show that DC-SCRIPT expression in ESR1? (estrogen receptor 1, gene encoding ERa) breast cancer cells induces G1 cell cycle arrest and acts as a novel regulator of the gene CDKN2B encoding the tumor suppressor protein p15ink4b. Moreover, we show that DC-SCRIPT correlates with CDKN2B expression in a cohort of 1,132 ESR1? -positive primary tumors of breast cancer patients.
Methods

Patients
The protocol to study biological markers associated with disease outcome was approved by the medical ethics committee of the Erasmus Medical Center Rotterdam, The Netherlands (MEC 02.953). The study was performed in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands (www.federa. org), and consent was not required. This retrospective study used 1,505 blind-coded freshly frozen primary tumor tissues of female patients with operable breast cancer from 1978 through 2000. The primary breast tumors were from patients with detailed clinical follow-up as previously described [4] .
Cell culture
The MCF7 cell line expressing rtTA2S-M2 (ATCC, Tet-On Ò Advanced, Clontech) was cultured in DMEM with glutamax (Invitrogen), supplemented with 10 % heat-inactivated fetal calf serum (FCS, Greiner Bio-One), 0.5 % antibiotic-antimycotics (Invitrogen), and 100 lg/mL G418 (Gibco) to select for the rtTA2s-M2 plasmid. Cells transfected with pTRE reporter constructs (see below) were cultured with additional hygromycin B (100 lg/mL, Calbiochem).
Generation of DC-SCRIPT inducible MCF7 cells DC-SCRIPT from pCATCH-DCSCRIPT [5] was cloned in the multiple cloning site of pTRE-tight (Clontech) vector as a BamH1/Xba1 insert. pTRE-tight was used as the control plasmid.
MCF7 cells expressing rtTA2S-M2 were transfected with pTRE-tight or pTRE-tight-DC-SCRIPT and co-transfected with a hygromycin B resistance marker using metafectene according to the manufactures protocol (Biontex). Two days after transfection the transfected cells were selected with 100 lg/mL hygromycin B and 100 lg/mL G418. After expanding the positively selected cells, single colonies were picked, expanded, and checked by PCR for complete genomic incorporation of the correct pTRE-tight vector. Clones containing the DC-SCRIPT vector were labeled MCF7SC, and control clones containing the empty vector were labeled MCF7EV. MCF7SC29, MCF7SC36, MCF7EV16, and MCF7EV37 were chosen for further studies. DC-SCRIPT protein expression in these cell lines was validated using Western blot as previously described [6] .
MTT assay MCF7SC or MCF7EV clones were plated at equal numbers in the presence of 0 (vehicle), 10, 100, or 1,000 ng/mL doxycycline at day 0, and medium was refreshed every second day with fresh doxycycline. Relative cell viability/ proliferation was determined by a MTT-based colorimetric cell proliferation assay (Sigma) after 5 days of culturing.
Cell cycle distribution MCF7 inducible cells were cultured with 0 or 100 ng/mL doxycycline and synchronized using serum starvation for 24 h. Cells were released in 10 % charcoal stripped FCS (cFCS) ± 10 nM E2 (Sigma) for 20 h, lysed in 1 g/L sodium-citrate buffer containing 0.1 mg/mL RNase A, 20 lg/mL propidium-iodide, and 0.1 % Triton, and analyzed for cell cycle distribution using bivariate flow cytometry on a FACSCalibur (BD). FlowJo software (TreeStar) was used for cell cycle position using the cell cycle algorithm.
In vivo MCF7SC/EV xenograft model All animal experiments were approved by the Animal Experimental Committee of the Radboud UMC and were performed in accordance with institutional, national and European guidelines. 6-8-week-old female BALB/c-nude mice (Janvier Labs) were inoculated orthotopically in the mammary fat pad with 5 9 10 6 MCF7SC29 or MCF7EV16. On the same day, a 60-day-slow release pellet containing 17b-estradiol (0.72 mg/pellet, Innovative Research of America) was implanted s.c. using a trochar for small pellet implantation (Innovative Research of America). Upon tumor establishment, mice were treated with 2 mg/mL doxycycline in normal drinking water or vehicle control. Mice weight was monitored every second day, and no significant differences were observed between experimental groups. Tumor size was measured every second day using a caliper, and volume was calculated as described in [22] . Part of the tumor xenografts were snapfrozen and embedded in OCT embedding matrix (CellPath) and stained for DC-SCRIPT as previously described [3] .
Microarray analysis
Genome-wide expression profiling of treated and untreated MCF7 cells was performed on a Illumina HumanHT-12 WG-DASL V4.0 R2 expression BeadChip according to the manufacturer's description. For this, total RNA was isolated by lysing cells cultured in 6-well plates followed by total RNA isolation with the Quick-RNA MiniPrep kit (zymo research) and quantified using Nanodrop. Next, 500 ng total RNA was amplified in the presence of UDG and after hybridization on the BeadChip scanned on an iScan Reader using the associated BeadScan software. Scanned data were uploaded into GenomeStudio Ò software (v2011.1) via the gene expression module (WG-DASL Assay), after which raw bead information was further normalized and analyzed with Lumi R package [23] . All normalized and non-normalized microarray data have been submitted to the GEO database (accession number GSE59995, reviewer link: http://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?token=gxsdeysonpuhlep&acc=GSE5 9995 [link will be removed before publication]).
In addition, in clinical breast cancer samples, ZNF366 mRNA levels (measured as described before [4] ) were compared with expression data we had available of 190 ESR1-positive LNN breast tumors that were analyzed before on the Affymetrix oligonucleotide Human U133a Gene Chips [24] [25] [26] , GEO accession numbers GSE2034 and GSE5327.
Gene ontology and pathway analysis was conducted using the Functional Annotation Tool at the DAVID Bioinformatics Resources [27, 28] .
RNA isolation and quantitative reverse transcriptase PCR (RT-qPCR) of MCF7 Total RNA was isolated and reverse transcribed into cDNA as described before [6] . mRNA levels for the genes of interest were determined with a CFX96 sequence detection system (Bio-Rad) with SYBR Green (Roche) as the fluorophore and gene-specific oligonucleotide primers. The primers for ZNF366 and the reference gene HMBS were described previously [3] . Other used primers are as follows: CDK6 (F-CCAGATGGCTCTAACCTCAGT, R-AACTTC CACGAAAAAGAGGCTT), and CDKN2B (F-CGAGGA GAACAAGGGCATGC, R-CTGTCGCACCTTCTCCAC TAG). Reaction mixtures and program conditions were used that were recommended by the manufacturer (BioRad). Quantitative PCR data were analyzed with the CFX Manager software (Bio-Rad) as described before [6] , and mRNA levels were calculated according to the cycle threshold method [29] .
RT-qPCR of patient samples
Tissue processing, RNA isolation, cDNA synthesis, and quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) were performed and normalized using the delta Cq method on the average of 3 reference genes (HMBS [F-CATGTCTGGTAACGGCAATG, R-GTACGAGGCTT TCAATGTTG], HPRT1 [F-TATTGTAAT GACCAGTCA ACAG, R-GGTCCTTTTCACCAGCAAG] and TBP [F-TT CGGAGAG TTCTGGGATTG, R-ACGAAGTGCAATGG TCTTTAG) as previously described [4, 30] . Quantification of target genes was done using the following intron-spanning Taqman probe-based gene expressions assays (Applied BioSystems): CDKN2B, Hs00793225_m1; and ZNF366, Hs00403536_m1 according the manufacturer's instructions. Other primers used to analyze mRNA expression by SYBR Green based real-time PCR in a Mx3000P Real-Time PCR System (Agilent) were as follows: CDK6: F-AGGTCTG GACTTTCTTCATTC, R-CTGGACTGGAGCAAGACTT C; ESR1: F-ATCCTACCAGACCCT TCAGTG, R-GCCAG ACGAGACCAATCATC. Samples were grouped in ESR1 negative and positive according the cut off at 0.2 as described in [31] .
Results
DC-SCRIPT expression in breast cancer patients negatively correlates with cell cycle genes
Previously, we reported that DC-SCRIPT is a unique NR modulator and that its mRNA expression is a strong and independent marker of favorable prognosis in ESR1-positive breast cancer [3, 4, 7, 8, 11] . To gain further insight into the functional role of DC-SCRIPT in breast cancer cells, DC-SCRIPT mRNA levels from 190 primary ESR1-positive breast tumors [4] was related with the global gene expression data that was available for these tumors. This analysis revealed that high DC-SCRIPT mRNA expression negatively correlated with several cell cycle gene ontologies and pathways (Table 1) . Cell cycle related genes negatively correlating with DC-SCRIPT mRNA included CDK2, CCNB1, CCNE2, and E2F1 (Table 2) . Intriguingly, a correlation with cell cycle proteins is precisely what one would expect of a protein inhibiting the activity of the proproliferative type I NRs ERa and PR and stimulating the activity of the mainly anti-proliferative NRs RAR and PPAR [3] .
DC-SCRIPT negatively regulates cell growth in breast cancer cell lines in vitro and in vivo
Previously, we have shown that prolonged (over)expression of DC-SCRIPT in the estrogen-responsive breast cancer cell line MCF7 transiently transfected with DC-SCRIPT resulted in growth inhibition of the DC-SCRIPT expressing cells [3] . To further validate this finding, the growth inhibitory effects of DC-SCRIPT were determined in an additional estrogen-responsive cell line CAMA-1 [32] . In agreement with our previous data on MCF7 cells, also cell growth of CAMA-1 cells could be inhibited by DC-SCRIPT expression (Appendix A in supplymentary material).
So far all cell lines analyzed were found to be essentially negative for endogenous DC-SCRIPT mRNA expression, including the above mentioned cell lines and 36 other breast carcinoma cell lines (data not shown). To circumvent the problem of the lack of DC-SCRIPT in cell lines for functional studies, DC-SCRIPT was cloned in front of the Tet-responsive promoter construct that becomes activated upon addition of doxycycline [MCF7 Tet-on advanced cell line (Clontech)]. Following transfection, multiple-independent clones expressing DC-SCRIPT (MCF7SC) upon stimulation with doxycycline or the empty control construct were isolated (MCF7EV) (data not shown). By varying the doxycycline concentration the expression levels of DC-SCRIPT can be varied and tuned toward a physiological level (Fig. 1a) . Relative to its endogenous expression levels in DCs, MCF7SC29 cells treated with 100 ng/mL doxycycline show physiological DC-SCRIPT expression levels. Using 100 ng/mL doxycycline, it was determined that DC-SCRIPT has a protein half-life of 4 h following doxycycline withdrawal (Fig. 1b) and that doxycycline addition every 48 h results in the continuous expression of DC-SCRIPT in these cells (data not shown).
Using an MTT assay, the effect of DC-SCRIPT expression on cell viability was assayed (Fig. 1c) . Increasing DC-SCRIPT expression levels affected cell viability in two independent MCF7SC clones, whereas the viability of MCF7EV16 was not affected by increasing levels of doxycycline (Fig. 1c) . Similar results were obtained from actual cell count after 6 days of DC-SCRIPT expression (Appendix B in supplymentary material).
To investigate the effect of DC-SCRIPT expression on breast tumor growth in vivo, MCF7SC29 or MCF7EV16 cells were inoculated orthotopically in the mammary fat pad of female nude mice. Simultaneously, an estradiol slow release pellet was implanted s.c. to stimulate tumor growth. 4 days after implantation when a palpable tumor was present, mice either received normal drinking water or watercontaining 2 mg/mL doxycycline to induce DC-SCRIPT expression (Fig. 2) . Strikingly, mice engrafted with the MCF7SC29 clone receiving doxycycline had a strongly diminished tumor growth compared to mice injected with the MCF7EV16 clone or mice receiving normal water (Fig. 2a) . In line with this, DC-SCRIPT induction in mice engrafted with MCF7SC29 extended their overall survival, whereas all control mice reached their endpoint (700 mm 3 ) before day 60, none of the mice engrafted with MCF7SC29 and receiving doxycycline reached this size before day 60 (data not shown). DC-SCRIPT expression in the tumor xenografts was confirmed by immunohistochemistry (Fig. 2b) . Altogether these data demonstrate that DC-SCRIPT expression in breast cancer cells represses cell growth in vitro and inhibits breast tumor growth in vivo.
DC-SCRIPT expression arrests breast cancer cells in G1
DC-SCRIPT mRNA expression in breast cancer patients negatively correlated with many cell cycle proteins ( Table 2 ), suggesting that DC-SCRIPT expression inhibits cell growth by affecting cell cycle progression. To investigate this hypothesis the MCF7SC and MCF7EV cells were synchronized by serum starvation for 24 h and then released in the presence or absence of estradiol (E2) to induce cell growth, and subjected to cell cycle analysis using bivariate flow cytometry. --------------------SC29 ---------------------- ------------------------SC29 ----------------------------- nM E2. In agreement with DC-SCRIPT expression in breast tumor specimens, also in the MCF7-DC-SCRIPT inducible model, multiple cell cycle-related genes are differentially expressed in the presence of DC-SCRIPT. In total, 22 cell cycle related genes were regulated more than 1.5 fold by DC-SCRIPT expression in MCF7 cells (Table 3) . Interestingly, the majority of cell cycle genes were downregulated upon DC-SCRIPT expression (17 out of 22) which is in line with the negative correlation between DC-SCRIPT expression and cell cycle genes from the breast cancer specimens (Tables 1, 2) . Notably, many of the 24 cell cycle genes found to be negatively correlated with DC-SCRIPT expression in the primary breast cancer specimens were also negatively regulated by DC-SCRIPT expression in the MCF7 DC-SCRIPT inducible system (Appendix C in supplymentary material). The two highest downregulated genes in the MCF7 system (MAPK13 and CYP26B1) affect cell cycle by secondary pathways via MAPK signaling [33] and retinoic acid metabolism [34, 35] , respectively. Interestingly, the two highest upregulated genes, CDKN2B and CDK6, affect cell cycle directly and belong to the same pathway regulating G1 cell cycle progression [36] . Both these genes' positive correlation with DC-SCRIPT expression was confirmed by RTqPCR in the MCF7 system (Fig. 4) , but both genes could not be reliably detected on the microarray platform used for the primary breast tumor specimens. Therefore, the CDKN2B and CDK6 mRNA expression level was assayed in the breast cancer cohort by RT-qPCR. Intriguingly, DC-SCRIPT mRNA expression levels also positively correlated with CDKN2B and CDK6 in 1,132 ESR1-positive breast cancer patients and much less in 324 ESR1-negatively breast cancer patients ( Fig. 5 ; Table 4 ), which is in line with our previous data showing that DC-SCRIPT has the strongest prognostic value in the ESR1-positive tumors [3, 4] . Taken together these data indicate that DC-SCRIPT expression correlates with multiple cell cycle related genes in breast cancer tissues and is involved in the regulation of the expression of the cell cycle inhibitor CDKN2B and CDK6.
Discussion
DC-SCRIPT expression level has been associated with a favorable prognosis in breast cancer [3, 4] , but the molecular mechanism responsible for this relationship is unknown. Applying an unbiased transcriptome profiling, we now report that DC-SCRIPT expression in breast cancer patients correlates with many cell cycle related genes. Using a novel DC-SCRIPT-inducible breast cancer cell line, we further show that DC-SCRIPT expression results in growth-and cell cycle-arrest both in vitro and in vivo. Additional transcriptome profiling revealed that the presence of DC-SCRIPT induces the expression of CDKN2B, the gene encoding the tumor suppressor protein p15ink4b. Interestingly, DC-SCRIPT mRNA also positively correlates with CDKN2B expression in 1,132 ESR1-positive breast cancer patients. The CDKN2B gene has been shown to be expressed in a range of breast cancer cell lines and normal mammary epithelial cell strains [37] . Moreover CDKN2B has previously been linked to cellular senescence and shown to act as a tumor suppressor protein [38, 39] . Our data now show that DC-SCRIPT expression in breast cancer cells induces G1 cell cycle arrest and enhances CDKN2B expression, suggesting that DC-SCRIPT inhibits breast cancer cell growth at least in part via CDKN2B up regulation. How DC-SCRIPT regulates CDKN2B expression is currently unknown. Interestingly, another zinc-finger protein ZNF217 has also been shown to regulate CDKN2B expression. ZNF217 inhibits CDKN2B expression by binding to the CDKN2B promoter, when present in a large multi-protein complex consisting of e.g., CtBP1 and HDAC1/2 [40, 41] . DC-SCRIPT is also known to be present in large multi-protein complexes consisting of CtBP1, HDAC1/3/6 and depending on the cell context, different NRs [3, 5, 7, 11] . Another protein that has been shown to induce CDKN2B expression and cell cycle arrest in non-transformed cells is TGFb [36, 42, 43] . Possibly via regulating TGFb expression or activity DC-SCRIPT could indirectly regulate CDKN2B. Inhibition of the protooncogene and ERa target PIM-1 has also been linked to the upregulation of CDKN2B and attenuated proliferation of MCF7 cells [44] . As DC-SCRIPT is known to act as corepressor protein of ERa [3, 11] , DC-SCRIPT may repress the estradiol-mediated expression of PIM-1 and thereby regulate CDKN2B expression and inhibit breast cancer cell growth. It will be extremely interesting to investigate the exact molecular mechanism, using for example, ChIP-Seq, by which DC-SCRIPT regulates directly or indirectly CDKN2B expression in breast (cancer) cells in future studies. CDKN2B is a specific inhibitor of CDK4 and CDK6, proteins that are important in cell cycle G1 phase progression and G1/S transition. Upon binding, p15ink4b diminishes cyclin D-mediated activation of these CDKs [36] . Intriguingly, together with the DC-SCRIPT-mediated CDKN2B upregulation, we also found CDK6 upregulation. This dual upregulation of a cell-cycle inhibitor and cell cycle activator has previously been observed [45] and may represent the tightly regulated balance of cell cycle proteins present during cell proliferation. Our data have shown that DC-SCRIPT expression is associated with many cell cycle regulators in a MCF7 breast cancer cell line as well as in primary breast cancer specimens. DC-SCRIPT expression skews the balance toward G1 arrest, resulting in diminished cell growth in vitro. Moreover, turning on DC-SCRIPT expression in established MCF7 breast tumors cells in nude mice strongly inhibits the outgrowth of these tumor cells in vivo. These data emphasize the dominant role of DC-SCRIPT in breast cancer cell growth.
Taken together, the data presented in this report demonstrate that DC-SCRIPT affects breast cancer cell cycle progression by displaying an effect on multiple cell (a) (b) Fig. 4 Induction of DC-SCRIPT upregulates the tumor suppressor CDKN2B and its target CDK6 in MCF7s. Purified RNA from synchronized MCF7SC29, MCF7SC36, and MCF7EV16 cells cultured with 100 ng/mL doxycycline, 20 h after 10 nM E2 stimulation were assayed by qPCR for a CDKN2B, and b CDK6 expression. Statistics was done by Mann-Whitney test, *p \ 0.05 (n = 3, error bars SEM)
cycle regulators including the upregulation of the cell cycle inhibitor CDKN2B. Ultimately, stimulation of DC-SCRIPT expression or regulation of its downstream targets in ESR1-positive breast cancer patients may turn out to be a clinically relevant therapeutic strategy to inhibit breast cancer growth. expression. Reliable expression data were correlated between DC-SCRIPT mRNA and CDKN2B using the spearman's rank correlation coefficient (two-tailed) in a ESR1-positive (n = 1,132), and b ESR1-negative (n = 324) patients. *p \ 0.05, ***p \ 0.001 1,504 breast cancer patients were grouped according to ESR1-positivity, and the spearman correlation coefficient was calculated between DC-SCRIPT mRNA (ZNF366) and CDKN2B and CDK6 *p \ 0.05, ***p \ 0.001
